同步放化疗联合β-榄香烯注射液治疗食管癌的临床研究(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 评价同步放化疗联合β-榄香烯注射液治疗食管癌的近期和远期疗效及毒副反应。 方法 将84例中晚期食管癌患者随机分成对照组和试验组，每组各42例，试验组采用同步放化疗+β-榄香烯注射液治疗，对照组单纯同步放化疗治疗。 结果 试验组1、2、3年局控率分别为83.3%、71.4%、52.4%，明显高于对照组，差异有统计学意义(P < 0. 05)；试验组1、2、3年的生存率分别为73.8%、57.1%和42.9%，也明显高于对照组 (P < 0.05)；而试验组治疗中晚期食管癌近期疗效以及治疗所致的放射性食管炎、放射性肺炎、胃肠道反应及骨髓抑制情况与对照组相比，差异无统计学意义(P > 0.05)。 结论 β-榄香烯注射液对食管癌同步放化疗具有协同作用，可提高食管癌患者局控率及生存率，且并不增加同步放化疗所致的毒副反应。
[关键词] β-榄香烯；食管癌；同步放化疗
[中图分类号] R735.1 [文献标识码] A [文章编号] 1673-7210(2012)04(a)-0069-03
Clinical research of concurrent chemoradiotherapy combined with β-Elemene Injection in the treatment of esophageal cancer
ZHOU Jian
Department of Oncology, Traditional Chinese Medicine Hospital of Changzhou City, Jiangsu Province, Changzhou 213003, China
[Abstract] Objective To evaluate the short-term and long-term efficacy and toxicity of concurrent chemoradiotherapy combined with β-Elemene Injection in the treatment of esophageal cancer. Methods 84 patients with advanced esophageal cancer were randomly divided into experiment group and control group, each group had 42 cases. The experiment group was treated with concurrent chemoradiotherapy+β-Elemene Injection, and the control group was only given radiotherapy and chemotherapy alone. Results In experiment group, the one, two and three-year local control rates were 83.3%, 71.4%, 52.4% respectively, which were significantly higher than those of the control group (P < 0.05). Meanwhile, one, two and three-year survival rates of experiment group were 73.8%, 57.1% and 42.9%, which were also significantly higher when compared with the control group (P < 0.05) . But there was no significant difference in short-term efficacy and treatment-induced adverse reactions including radiation esophagitis, radiation pneumonitis, gastrointestinal reactions and inhibition of bone marrow, when compared with the control group of patients (P > 0.05). Conclusion β-Elemene Injection with a synergy effect when combined with concurrent chemoradiotherapy can improve the local control rate and survival rate in patients with esophageal cancer, and without increasing the adverse reactions induced by concurrent chemoradiationtherapy ......
您现在查看是摘要介绍页，详见PDF附件(2436kb)。